TABLE OF CONTENTS
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW OF THE EUROPE IN-VITRO TOXICOLOGY TESTING MARKET 40
1.4 CURRENCY AND PRICING 42
1.5 LIMITATIONS 42
1.6 MARKETS COVERED 42
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 DBMR TRIPOD DATA VALIDATION MODEL 48
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
2.6 MULTIVARIATE MODELLING 52
2.7 PRODUCT AND SERVICE SEGMENT LIFELINE CURVE 52
2.8 MARKET END USER COVERAGE GRID 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 55
2.11 SECONDARY SOURCES 56
2.12 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 60
4.1 PESTEL ANALYSIS 61
4.2 PORTERS ANALYSIS 62
5 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, INDUSTRY INSIGHTS 63
6 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, REGULATIONS 65
7 MARKET OVERVIEW 68
7.1 DRIVERS 70
7.1.1 INCREASING DEMAND FOR TOXICOLOGY TESTING PRODUCTS 70
7.1.2 RAPIDLY GROWING PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRIES 70
7.1.3 RISING INVESTMENT IN R&D BY KEY MARKET PLAYERS 71
7.1.4 TECHNOLOGICAL ADVANCEMENTS TO DEVELOP NEW TOXICOLOGY TESTING METHODS 71
7.2 RESTRAINTS 72
7.2.1 HIGH COSTS ASSOCIATED WITH IN-VITRO TOXICOLOGY TESTING AND PRODUCTS 72
7.2.2 COMPLEXITY OF BIOLOGICAL SYSTEMS 72
7.2.3 NEED FOR SKILLED PERSONNEL AND INFRASTRUCTURE 73
7.3 OPPORTUNITIES 73
7.3.1 GROWING ADOPTION OF QUALITY CHECK PRODUCTS TO PREVENT PRODUCT RECALLS 73
7.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS FOR MARKET EXPANSION 74
7.3.3 GROWING DEMAND FOR PERSONALIZED MEDICINE AND PRECISION TOXICOLOGY 74
7.4 CHALLENGES 75
7.4.1 ETHICAL AND PUBLIC PERCEPTION 75
7.4.2 REGULATORY ACCEPTANCE AND ENDORSEMENT OF IN-VITRO TESTING METHODS 75
8 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT AND SERVICE 76
8.1 OVERVIEW 77
8.2 CONSUMABLES 80
8.3 SERVICES 81
8.3.1 CYTOTOXICITY 82
8.3.2 GENE TOXICITY 82
8.3.3 HEPATOTOXICITY 82
8.3.4 OPHTHALMIC TOXICITY 82
8.3.5 CARDIOTOXICITY 82
8.3.6 NEPHROTOXICITY 82
8.3.7 NEUROTOXICITY 83
8.3.8 OTHERS 83
8.4 ASSAYS 83
8.4.1 CELL-BASED ELISA & WESTERN BLOTS 84
8.4.2 ENZYME TOXICITY ASSAYS 84
8.4.3 RECEPTOR-BINDING ASSAYS 84
8.4.4 BACTERIAL TOXICITY ASSAYS 84
8.4.5 TISSUE CULTURE ASSAYS 84
8.4.6 OTHER ASSAYS 84
8.5 EQUIPMENTS 85
8.6 SOFTWARE 86
9 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT AND TEST 87
9.1 OVERVIEW 88
9.2 ADME (ABSORPTION, DISTRIBUTION, METABOLISM, & EXCRETION) TESTING 91
9.3 CYTOTOXICITY TESTING 92
9.4 GENOTOXICITY TESTING 93
9.5 DERMAL TOXICITY TESTING 94
9.6 OCULAR TOXICITY TESTING 95
9.7 ORGAN TOXICITY TESTING 96
9.8 SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING 97
9.9 PHOTOTOXICITY TESTING 97
9.10 OTHER TOXICITY ENDPOINTS AND TESTS 98
10 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY 100
10.1 OVERVIEW 101
10.2 CELL CULTURE TECHNOLOGIES 104
10.3 HIGH-THROUGHPUT TECHNOLOGIES 105
10.4 MOLECULAR IMAGING 106
10.5 OMICS TECHNOLOGY 107
11 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, BY METHOD 108
11.1 OVERVIEW 109
11.2 CELLULAR ASSAYS 111
11.3 BIOCHEMICAL ASSAYS 112
11.4 EX-VIVO MODELS 113
11.5 IN SILICO MODELS 114
12 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY 116
12.1 OVERVIEW 117
12.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 120
12.2.1 CONSUMABLES 121
12.2.2 SERVICES 121
12.2.3 ASSAYS 121
12.2.4 EQUIPMENTS 121
12.2.5 SOFTWARE 121
12.3 DIAGNOSTICS 121
12.3.1 CONSUMABLES 123
12.3.2 SERVICES 123
12.3.3 ASSAYS 123
12.3.4 EQUIPMENTS 123
12.3.5 SOFTWARE 123
12.4 FOOD 123
12.4.1 CONSUMABLES 124
12.4.2 SERVICE 124
12.4.3 ASSAYS 124
12.4.4 EQUIPMENTS 125
12.4.5 SOFTWARE 125
12.5 CHEMICALS 125
12.5.1 CONSUMABLES 126
12.5.2 SERVICES 126
12.5.3 ASSAYS 126
12.5.4 EQUIPMENTS 126
12.5.5 SOFTWARE 126
12.6 COSMETICS AND HOUSEHOLD PRODUCTS 127
12.6.1 CONSUMABLES 128
12.6.2 SERVICES 128
12.6.3 ASSAYS 128
12.6.4 EQUIPMENTS 128
12.6.5 SOFTWARE 128
13 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, BY DISTRIBUTION CHANNEL 129
13.1 OVERVIEW 130
13.2 DIRECT TENDER 132
13.3 RETAIL SALES 133
13.4 OTHERS 134
14 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, BY REGION 136
14.1 EUROPE 137
14.1.1 GERMANY 146
14.1.2 U.K. 151
14.1.3 FRANCE 156
14.1.4 ITALY 161
14.1.5 RUSSIA 166
14.1.6 SPAIN 171
14.1.7 NETHERLANDS 176
14.1.8 2.8 SWITZERLAND 181
14.1.9 BELGIUM 186
14.1.10 TURKEY 191
14.1.11 REST OF EUROPE 196
15 EUROPE IN-VITRO TOXICOLOGY TESTING MARKET, COMPANY LANDSCAPE 197
15.1 COMPANY SHARE ANALYSIS: EUROPE 197
16 SWOT ANALYSIS 198
17 COMPANY PROFILE 199
17.1 THERMO FISHER SCIENTIFIC INC. 199
17.1.1 COMPANY SNAPSHOT 199
17.1.2 REVENUE ANALYSIS 199
17.1.3 COMPANY SHARE ANALYSIS 200
17.1.4 PRODUCT PORTFOLIO 200
17.1.5 RECENT DEVELOPMENT 200
17.2 LABCORP DRUG DEVELOPMENT 201
17.2.1 COMPANY SNAPSHOT 201
17.2.2 REVENUE ANALYSIS 201
17.2.3 COMPANY SHARE ANALYSIS 202
17.2.4 PRODUCT PORTFOLIO 202
17.2.5 RECENT DEVELOPMENT 202
17.3 MERCK KGAA 203
17.3.1 COMPANY SNAPSHOT 203
17.3.2 REVENUE ANALYSIS 203
17.3.3 COMPANY SHARE ANALYSIS 204
17.3.4 PRODUCT PORTFOLIO 204
17.3.5 RECENT DEVELOPMENT 204
17.4 CHARLES RIVER LABORATORIES. 205
17.4.1 COMPANY SNAPSHOT 205
17.4.2 REVENUE ANALYSIS 205
17.4.3 COMPANY SHARE ANALYSIS 206
17.4.4 PRODUCT PORTFOLIO 206
17.4.5 RECENT DEVELOPMENT 206
17.5 LONZA 207
17.5.1 COMPANY SNAPSHOT 207
17.5.2 REVENUE ANALYSIS 207
17.5.3 COMPANY SHARE ANALYSIS 208
17.5.4 PRODUCT PORTFOLIO 208
17.5.5 RECENT DEVELOPMENT 208
17.6 AAT BIOQUEST, INC. 209
17.6.1 COMPANY SNAPSHOT 209
17.6.2 PRODUCT PORTFOLIO 209
17.6.3 RECENT DEVELOPMENTS 209
17.7 ARAGEN LIFE SCIENCES LTD. 210
17.7.1 COMPANY SNAPSHOT 210
17.7.2 REVENUE ANALYSIS 210
17.7.3 PRODUCT PORTFOLIO 211
17.7.4 RECENT DEVELOPMENT 211
17.8 BIOIVT 212
17.8.1 COMPANY SNAPSHOT 212
17.8.2 PRODUCT PORTFOLIO 212
17.8.3 RECENT DEVELOPMENT 212
17.9 BIO-RAD LABORATORIES, INC. 213
17.9.1 COMPANY SNAPSHOT 213
17.9.2 REVENUE ANALYSIS 213
17.9.3 PRODUCT PORTFOLIO 214
17.9.4 RECENT DEVELOPMENT 214
17.10 CATALENT, INC 215
17.10.1 COMPANY SNAPSHOT 215
17.10.2 REVENUE ANALYSIS 215
17.10.3 PRODUCT PORTFOLIO 216
17.10.4 RECENT DEVELOPMENT 216
17.11 CREATIVE BIOARRAY. 217
17.11.1 COMPANY SNAPSHOT 217
17.11.2 PRODUCT PORTFOLIO 217
17.11.3 RECENT DEVELOPMENTS 217
17.12 CREATIVE BIOLABS. 218
17.12.1 COMPANY SNAPSHOT 218
17.12.2 PRODUCT PORTFOLIO 218
17.12.3 RECENT DEVELOPMENTS 218
17.13 CYPROTEX LIMITED 219
17.13.1 COMPANY SNAPSHOT 219
17.13.2 PRODUCT PORTFOLIO 219
17.13.3 RECENT DEVELOPMENT 219
17.14 EUROFINS SCIENTIFIC 220
17.14.1 COMPANY SNAPSHOT 220
17.14.2 REVENUE ANALYSIS 220
17.14.3 PRODUCT PORTFOLIO 221
17.14.4 RECENT DEVELOPMENT 221
17.15 GENTRONIX 222
17.15.1 COMPANY SNAPSHOT 222
17.15.2 PRODUCT PORTFOLIO 222
17.15.3 RECENT DEVELOPMENT 222
17.16 IONTOX 223
17.16.1 COMPANY SNAPSHOT 223
17.16.2 PRODUCT PORTFOLIO 223
17.16.3 RECENT DEVELOPMENT 223
17.17 INSPHERO. 224
17.17.1 COMPANY SNAPSHOT 224
17.17.2 PRODUCT PORTFOLIO 224
17.17.3 RECENT DEVELOPMENT 224
17.18 INTERTEK GROUP PLC 225
17.18.1 COMPANY SNAPSHOT 225
17.18.2 REVENUE ANALYSIS 225
17.18.3 PRODUCT PORTFOLIO 226
17.18.4 RECENT DEVELOPMENT 226
17.19 MB RESEARCH LABORATORIES 227
17.19.1 COMPANY SNAPSHOT 227
17.19.2 PRODUCT PORTFOLIO 227
17.19.3 RECENT DEVELOPMENTS 227
17.20 PREFERRED CELL SYSTEMS 228
17.20.1 COMPANY SNAPSHOT 228
17.20.2 PRODUCT PORTFOLIO 228
17.20.3 RECENT DEVELOPMENTS 228

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.